MONTHLY DOSE

MARCH 2019

MONTHLY DOSE

JULY 2021

Key News for the Month

Company Cipla partners with IIT Delhi backed startup Clensta for distribution of waterless technology products

Dr. Reddy's launches cancer drug in Canada

Biological E gets nod for phase 2/3 clinical trial of its Covid vaccine on children above 5 years, adolescents

Dr. Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777

Zydus Cadila gets USFDA nod for diabetes medication

Lupin, TB Alliance join hands for new therapy for drug-resistant tuberculosis

Hetero gets DGCI approval for generic version of tocilizumab for treatment of Covid-19

Panacea Biotec supplies second component of Sputnik V vaccine in India

ABB commissions ACS560 drives at Bharat Biotech's facility for safe manufacturing of Covaxin

Biocon inks patent litigation settlement pact with Celgene

Sun Pharma forays into nutrition bar segment with launch of Revital NXT

Moderna working on booster to combine Covid-19 vaccine with a flu shot

Centre places purchase order with SII for 66 crore Covishield doses to be supplied by December: Sources

Serum Institute may face delay in Covovax launch

Drug makers Granules India, Jubilant Cadista recall products in US market

Serum Institute may face delay in Covovax launch

Drug makers Granules India, Jubilant Cadista recall products in US market

NCLT approves amalgamation of Lincoln Parenteral & Lincoln Pharmaceuticals

Biocon Biologics, Serum Institute Life Sciences to expand tie-up for R&D, new vaccines

Serum Institute to invest USD68mn in UK vaccine maker Oxford Biomedica

Novovax, Serum Institute seek WHO's approval for their Covid vaccine

AstraZeneca invests in Imperial's self-amplifying RNA technology with eye on future drugs

Shilpa Medicare to make Cadila's Covid-19 vaccine

Lupin forays into diagnostics business; launch expected next month

Sun Pharma launches Chericof 12 in India

Industry Government slashes prices of about 39 commonly-used drugs

Govt sets up panel to frame new laws for drugs, devices and cosmetics

Multi-vitamin supplement sales drop as Covid cases reduce

Importers, makers of Covid-related items under NAA lens, CCI may join probe too

Global Human Biosciences plans to launch 2 wound care products in India

Moderna to collaborate with AbCellera

Novartis expands gene therapy pipeline with Arctos Medical takeover

FDA OKs Pfizer/BioNTech booster doses for higher-risk populations

Page 1

Final ANDA Approvals

Company API Strengths Indications Brand (Company) Mkt Size

Alembic Pharma

Metronidazole Gel 1% Indicated for the topical treatment of inflammatory lesions of rosacea

Metrogel Gel {Galderma Laboratories LP (Galderma)}

USD29mn

Caplin Point Labetalol Hydrochloride Injection

100mg/20mL (5mg/mL) and 200mg/40mL (5mg/mL) Multiple-dose Vials

Indicated for control of blood pressure in severe hypertension

TRANDATE Injection (Sebela Ireland Limited)

USD6mn (annual sales)

Glenmark Clindamycin Phosphate Foam

1% Used on the skin (topical) to treat acne in people 12 years and older

Evoclin Foam (Mylan Pharmaceuticals Inc.)

USD12mn (annual sales)

Source: Media Reports and Company Press Releases

Page 2

Tentative ANDA Approvals

Company API Strengths Indications Brand (Company) Mkt Size

Cadila Sitagliptin Tablets

25/50/100mg Helps control blood sugar levels

Januvia (Merck) -

Cadila Brexpiprazole Tablets

0.25/0.5/1/2/3/4mg

indicated for use as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD) and for treatment of schizophrenia

Rexulti Tablets (Otsuka Pharmaceutical)

-

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance

Companies Price Change

1 M 6 M 12 M

IPCA Laboratories Ltd 2408 -2.9% 27.5% 11.1%

J.B.Chemicals & Pharma Ltd. 1865 9.7% 51.9% 88.9%

Laurus Labs Ltd 617.1 -5.0% 71.3% 115.0%

Lincoln Pharmaceuticals Ltd 412 21.8% 84.9% 58.1%

Lupin Ltd 951 -0.2% -5.5% -5.6%

Marksans Pharma Ltd 69 -5.7% 39.1% 37.2%

Max Healthcare Institute Ltd 360 0.4% 75.2% 212.0%

Metropolis Healthcare Ltd 2700 -3.1% 20.0% 50.4%

Morepen Laboratories Ltd 57 6.9% 79.0% 130.8%

Narayana Hrudayalaya Ltd 502 -5.4% 24.3% 40.2%

Natco Pharma Ltd 891 -5.9% 8.3% -6.2%

Neuland Laboratories Ltd 1552 -7.7% -26.5% 35.2%

Novartis India Ltd 818 4.8% 48.4% 31.9%

Panacea Biotec Ltd 286 -3.7% 59.0% 54.8%

Pfizer Ltd (India) 5580 -2.6% 25.0% 13.9%

Poly Medicure Ltd 927 -1.3% 13.3% 102.7%

Procter & Gamble Health Ltd 5415 -1.4% -13.6% 8.2%

RPG Life Sciences Ltd 686 37.0% 87.1% 72.2%

Sanofi India Ltd 7796 -11.6% -1.2% -9.8%

Sequent Scientific Ltd 220 -5.5% -8.6% 43.0%

Shalby Ltd 176 -8.7% 70.7% 99.1%

Shilpa Medicare Ltd 557 -3.1% 65.8% -0.6%

Solara Active Pharma Sciences Ltd 1600 -0.2% 18.5% 48.7%

Strides Pharma Science Ltd 589 -3.1% -32.0% -18.1%

SPARC Ltd 296 -1.4% 104.2% 70.5%

Sun Pharmaceutical Industries Ltd 818 4.0% 36.9% 63.5%

Suven Life Sciences Ltd 93 11.6% 31.2% 85.2%

Suven Pharmaceuticals Ltd 532 -2.4% 11.0% 40.2%

Syngene International Ltd 600 -4.8% 12.1% 8.3%

Take Solutions Ltd 51 -2.9% 11.7% 10.7%

Thyrocare Technologies Ltd 1166 -4.9% 33.4% 53.7%

Torrent Pharmaceuticals Ltd 3077 -0.5% 21.6% 9.9%

Unichem Laboratories Ltd 271 -7.2% -13.3% 10.7%

Vimta Labs Ltd 280 -6.5% 82.8% 136.6%

Wockhardt Ltd 455 11.7% 5.8% 54.4%

BSE Health Care Index Price Performance

Companies Price Change

1 M 6 M 12 M

Aarti Drugs Ltd 608 -0.03% -14.2% -21.3%

Abbott India Ltd 20528 7.6% 36.3% 24.4%

Ajanta Pharma Ltd 2282 2.4% 22.3% 41.5%

Albert David Ltd 598 2.5% 57.2% 35.6%

Alembic Ltd 115 10.1% 13.3% 9.7%

Alembic Pharmaceuticals Ltd 789 5.0% -17.6% -15.8%

Alkem Laboratories Ltd 3980 1.9% 45.2% 43.2%

Apollo Hospitals Enterprise Ltd 4485 -5.7% 53.1% 108.6%

Aster DM Healthcare Ltd 208 -3.4% 51.8% 56.7%

AstraZeneca Pharma India 3090 -0.7% 1.6% -28.1%

Aurobindo Pharma Ltd 726 1.4% -16.6% -8.9%

Biocon Ltd 363 1.8% -11.2% -19.0%

Bliss GVS Pharma Ltd 110 -2.2% 9.3% -35.6%

Cadila Healthcare Ltd 552 -0.5% 27.1% 39.8%

Caplin Point Laboratories Ltd 885 20.8% 115.4% 59.9%

Cipla Ltd 984 5.2% 21.1% 27.0%

Dishman Carbogen Amics Ltd 200 6.5% 84.2% 27.7%

Divi's Laboratories Ltd 4799 -6.1% 33.9% 57.5%

Dr. Reddy's Laboratories Ltd 4886 4.43% 8.1% -5.8%

Dr. Lal PathLabs Ltd 3678 -7.2% 40.5% 95.8%

Eris Lifesciences Ltd 760 4.3% 24.7% 41.2%

FDC Ltd 349 0.3% 24.3% -2.0%

Fermenta Biotech Ltd 271 -5.5% 6.8% -25.0%

Fortis Healthcare Ltd 263 -7.8% 31.5% 94.7%

Gland Pharma Ltd 3730 -4.0% 49.5% -

GSK Pharmaceuticals Ltd 1481 -2.8% 3.9% -5.9%

Glenmark Pharmaceuticals Ltd 510 -3.3% 10.5% 5.8%

Granules India Ltd 320 -3.5% 3.6% -16.5%

Gufic Biosciences Ltd 194 3.7% 84.7% 115.0%

HealthCare Global Enterprises Ltd 247 7.1% 36.4% 104.4%

Hester Biosciences Ltd 2488 4.4% 31.1% 46.2%

Hikal Ltd 603 -6.7% 315.7% 215.9%

Indoco Remedies Ltd 449 -3.7% 56.8% 75.2%

Indraprastha Medical Corp. Ltd 79 4.9% 45.5% 56.5%

IOL Chemicals and Pharma Ltd 594 6.6% 6.6% -18.2%

Source: BSE website; All prices are as on 30th Sept, 2021

Page 3

Source: BSE website; All prices are as on 30th Sept, 2021

NIFTY PHARMA COMPANIES

Company Price (Rs)

Mcap (Rs mn)

Change

1 M 6 M 12 M

Aurobindo Pharma Ltd. 726 425421 1.35% -16.6% -8.9%

Biocon Ltd. 363 435420 1.8% -11.2% -19.0%

Cadila Healthcare Ltd. 552 565055 -0.5% 27.1% 39.8%

Cipla Ltd. 984 793772 5.2% 21.1% 27.0%

Divi's Laboratories Ltd. 4799 1273931 -6.1% 33.9% 57.5%

Dr. Reddy's Laboratories Ltd. 4886 812769 4.4% 8.1% -5.8%

Alkem Laboratories Ltd. 3980 475875 1.9% 45.2% 43.2%

Lupin Ltd. 951 431684 -0.2% -5.52% -5.6%

Torrent Pharmaceuticals Ltd. 3077 520664 -0.5% 21.59% 9.9%

Sun Pharmaceutical Industries Ltd. 818 1963136 4.0% 36.9% 63.5%

Source: NSE website, Company Research; All prices are as on 30th Sept, 2021

Nifty Pharma Index Vs. Nifty Index

Source: NSE website

Page 4

DISCLAIMERS AND DISCLOSURES- Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products. PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-: · PSBPL or its associates financial interest in the subject company: NO · Research Analyst (s) or his/her relative's financial interest in the subject company: NO · PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company. · PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO · Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO · PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months. · The research Analyst has served as officer, director or employee of the subject company: NO PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Terms & Conditions: This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Compliance Officer: Mr. Shyam Agrawal,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Registered Office Address: Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai—400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500.